Fulvestrant in FALCON trial improves PFS in advanced breast cancer

Share :
Published: 8 Oct 2016
Views: 2853
Dr Matthew Ellis - Washington University in St Louis, USA

Dr Ellis talks to ecancertv at ESMO 2016 about the finding that fulvestrant significantly increased progression-free survival in women with hormone-receptor-positive advanced breast cancer, and particularly those with less aggressive lower-volume disease.

Read the news story for more.

These results were also discussed by Prof John Roberston here.